The American Society of Clinical Oncology’s annual meeting, one of the most important cancer conferences of the year, concluded June 7th.

This year’s theme was ‘collective wisdom: the future of patient-centered care and research,’ which ASCO says emphasizes the need to combine knowledge from various disciplines, cancer types, treatment approaches, and big data technologies in order to make progress. Here are some of this year’s highlights:

ASCO 2016 Preview: Expect data on CDK inhibitors, CAR-T therapies, and pricing – Competition among new breast cancer drugs, an immunotherapy contender, and pricing discussions headline one of the biggest cancer conferences of the year.

Multiple Myeloma –
ASCO 2016 Multiple Myeloma Update – Poster Presentations …

ASCO 2016 Multiple Myeloma Update – Days One, Two, And Three

ASCO 2016 Multiple Myeloma Update – Days Four & Five …

Genitourinary Cancer –
ASCO 2016: Nivolumab Effective in Metastatic Bladder Cancer, Regardless of Tumor PD-L1 Status

Nivolumab is safe and effective in patients with metastatic bladder cancer refractory to prior lines of platinum-based chemotherapy, according to findings from the open-label, phase I/II CheckMate 032 trial. Read More »

ASCO 2016: Nivolumab Treatment Beyond Progression Benefits Patients With Metastatic RCC
Anti-programmed cell death protein 1 (PD-1) checkpoint inhibitor immunotherapy with nivolumab is safe and effective even after disease progression among patients with metastatic RCC. Read More »

Lung Cancer –
ASCO 2016: Nivolumab Alone or With Ipilimumab Effective in SCLC Lauren Evoy Davis
June 07, 2016 | Lung Cancer Targets
Patients with relapsed small cell lung cancer now have more options according to study results first presented at the 2016 ASCO Annual Meeting, held June 3–7, 2016, in Chicago.

New Drugs/FDA Approvals –
FDA Approves Ibrutinib as First-Line CLL Treatment | OncoTherapy Network
The FDA recently approved ibrutinib (Imbruvica) for initial treatment of chronic lymphocytic leukemia (CLL), the first chemotherapy-free treatment option approved by the agency for first-line CLL patients. Read More »
FDA Approves Nivolumab for Relapsed Classical Hodgkin Lymphoma | OncoTherapy Network
The US Food and Drug Administration (FDA) granted accelerated approval of nivolumab (Opdivo) based on overall response rate (ORR) in classical Hodgkin lymphoma patients. Read More »

New Approaches to Treatment –
Better Survival for Colon Cancer Patients with Left-Sided Tumors

Putting Leukemia Patients Into Remission With Immunotherapy
Researchers in Seattle are reporting success with an experimental therapy that modifies T cells to express a CD19-specific chimeric antigen receptor (CAR) to treat B-cell malignancies. Read More »
Daratumumab Significantly Decreased Progression, Death for Relapsed Myeloma
A three-drug regimen that includes daratumumab, bortezomib, and dexamethasone may be the new standard of care for patients with relapsed or refractory multiple myeloma. Read More »

Adoptive T-Cell Therapy Next Step in Treating Melanoma
Induced pluripotent stem cells (iPSC) may provide an unlimited number of phenotypically defined, functional and expandable autologous antigen-specific T cells with the characteristics needed to combat cancer. Read More »

Case: Dual Immunotherapy Induced Remission in Metastatic Melanoma
Case: Dual Immunotherapy Induced Remission in Metastatic Melanoma Published on OncoTherapy Network Case: Dual Immunotherapy Induced Remission in Metastatic Melanoma News. June 03, 2016 | Skin CancerRead More »